Elsevier and European Alliance of Associations for Rheumatology announce new partnership

The European Alliance of Associations for Rheumatology (EULAR) announces a new partnership with Elsevier, a global leader in information and analytics, to publish its flagship scientific journal, Annals of the Rheumatic Diseases (ARD). The journal will be hosted on Elsevier’s leading online platform, ScienceDirect, beginning January 2025

“We are delighted that our flagship journal will continue its successful journey with the world's largest publisher and feel that this partnership will equip us ideally for the challenges of the future,” said Professor Daniel Aletaha, EULAR President.

Professor Josef Smolen, ARD Editor-in-Chief, adds: “Authors, researchers and readers can expect a seamless transition while maintaining the journal's high standards and commitment to excellence.”

Originally published in 1939, ARD has always strived for excellence in research advances and novel clinical insights. Thus, it continues to be the leading rheumatology journal publishing high-quality scientific papers, original research, reviews, recommendations, viewpoints, and more. Basic, clinical, and translational scientific research across the inflammatory and non-inflammatory musculoskeletal conditions is part and parcel of this spectrum.

The journal’s authors, reviewers and editors volunteer their time and expertise to contribute and disseminate this important scientific information to the international research community with a hybrid subscription-based model. Its current (2023) Impact Factor of 20.3 places it second overall in the Rheumatology subject category and first among the journals publishing original research advances. The 2023 CiteScore of 35 places it in the #1/73 (99^th percentile) position in the category Medicine/Rheumatology.

“We are very honoured to be chosen as the publishing partner for EULAR. Elsevier is committed to providing EULAR with a trusted platform, addressing customer needs, and providing insight through data analytics. Our collaboration will further support both organisations’ efforts to improve health outcomes”, stated Carl Schwarz, Senior Vice President, Health and Medical Sciences at Elsevier. “ARD is a hugely respected journal in the rheumatology field and will be a great fit with our rheumatology portfolio. We are very proud that EULAR has chosen to partner with us and look forward to helping them and ARD transition to Elsevier,” added Tanya Wheatley, Elsevier’s Executive Publisher for Rheumatology.

About the European Alliance of Associations for Rheumatology (EULAR)

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

エルゼビアについて

エルゼビアは、先端情報と意思決定を支援しています。1世紀以上にわたり、人類の進歩のため先端科学とヘルスケアの進歩に貢献してきました。私たちは、170か国にわたるアカデミアや企業の研究コミュニティ、医師、看護師、未来の医療従事者、教育者の皆さまの重要な活動をサポートしています。これは、信頼できるエビデンスに基づく科学・医療コンテンツと高度なAI技術を組み合わせた革新的なソリューションにより知見の集積や重要な意思決定を支援することで実現しています。また、私たちは、これらの価値を製品や企業文化に組み込み、コミュニティとの協働を通じて、インクルージョンと持続可能性を推進しています。エルゼビア財団は、世界中の研究と医療のパートナーシップを支援しています。

エルゼビアは、専門家およびビジネス向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Groupの一事業を担っています。詳細につきましては、www.elsevier.comソーシャルメディア@Elsevier Connectをご覧ください。